Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at Nordic Precision Medicine Forum 2023——Facilitating Global Collaboration

Page View:


Nordic Precision Medicine Forum 2023 is only a couple weeks away! Our VP of Strategic Collaborations EMEA, Dr. Paul G.J. van Stralen, our EVP and Head of IDSU, Dr. Xuedong Dai are invited to attend and exhibit at the conference. Medicilon team will be present throughout the conference. We are happy to meet you in person to discuss how our services and capabilities in chemistry, biology, in vivo and in vitro animal models, IND filling would support your current research needs and expedite your drug discovery and development programs.

Date: April 27-28, 2023

Location: Münchenbryggeriet, Stockholm

Meet with Medicilon
Subject丨Nordic Precision Medicine Forum 2023

About Nordic Precision Medicine Forum 2023

Across the Nordic countries precision medicine and technology developments continue at pace. Collaborative efforts and investment in diagnostics and digital health continue to grow placing the Nordic countries in a favourable position when it comes to taking on the opportunities and challenges of implementing precision medicine. With a focus on initiatives at a Nordic level and a global level, Nordic Precision Medicine Forum 2023 aims to bring a picture of the current state of the precision medicine world. 

About Medicilon

Medicilon is an integrated contract research organization (CRO) providing comprehensive one-stop services from initial idea to IND enabling studies and API manufacture for biotech, pharmaceutical companies and research institutions. With over 19 years’ experience in serving drug discovery, we have built an integrated technical platform covering, small molecule and large molecule drug discovery, in vivo and in vitro pharmacology, and preclinical IND enabling capabilities, to support drug development for today’s dynamic industry.

Our clients include not only pharmaceutical companies such as Roche, GSK and AZ, but also many global SMEs including start-up companies, R&D companies and Universities. Medicilon delivers both non-GLP and GLP safety studies generating data that is fully accepted by FDA, EMA, NMPA and TGA agencies. Our GLP in vivo laboratory is an AAALAC accredited international standard laboratory, audited and approved by NMPA and FDA. Since 2015, Medicilon has successfully assisted 331 new drug and generic drug projects to enter clinical trials by NMPA, FDA, and TGA, which accelerates the customer's new drug development process!

At Medicilon, we offer a full range of preclinical CRO services covering all phases of a client’s project. Customers can work with us via different business models including FFS, FTE or special flexible payment structures designed to help small biotech companies with cash flow and to achieve tight project delivery timelines. Medicilon is a dedicated CRO service provider without any internal drug discovery projects. Throughout 19 year history, Medicilon has fully respected customer Intellectual property.

Medicilon develops new technology platforms constantly, working in partnership with our global clients to deliver demanding and innovative novel drug research. Up to 2022, Medicilon has successfully developed more than 100 preclinical candidates for our global clients. In the preclinical candidate stage, Medicilon screens out lead compounds with high activity and selectivity through high-throughput screening and AI design, and further optimize the lead compounds (including physicochemical properties, early druggability, metabolic stability, pharmacokinetics, toxicity prediction, etc.) to obtain the candidate compound (PCC) and back-up compound, to further enable the research work in the IND stage.

At Medicilon, we are passionate about our role in novel drug discovery and research to improve people's health. We focus on timelines and applying multidisciplinary perspective in resolving our global clients’ research challenges and providing cost effective solutions to deliver quality data in every stage of drug research and development.

19+ years R&D Experience Since 2004

268 New Drugs Approved by NMPA, FDA, EMA, and TGA

1710+ Clients Worldwide

3500+ Scientists & Research staff

87,500m2 Laboratories and Facilities 

Overview of Medicilon R&D technology platforms


Featured Platform-PROTAC

PROTACs offer a fast and reversible chemical knock-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 3 PROTAC drugs by NMPA and/or FDA and has more than 20 PROTAC projects under development.

Medicilon has:
• Know-how: > 6 years PROTACs experience
• Comprehensiveness: > 20 ongoing projects
• Talent: > 300 dedicated well-trained chemists
• Team: > 300 dedicated well-trained chemists
• Building Block: > 300 advanced linkers Available
• Scaffold: > 150 E3 ligands available including Cereblon, VHL, MDM2, IAP, etc.

Featured Platform-ADC

Medicilon started ADC non-clinical research in 2014. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 13 ADC drugs by NMPA and/or FDA and has more than 10 ADC projects under development. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins.

Featured Platform-Antibody

With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 17 monoclonal antibody drugs and 7 bispecific antibody drugs by NMPA, FDA, and TGA.

Nucleic Acid Drug

Medicilon nucleic acid drug R&D platform provides an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Oriented with a rigorous scientific approach, an open-minded teamwork spirit and state-of-the-art equipment, our integrated solution will help clients and partners to fulfil their research and development mission for cutting-edge and innovative nucleic acid drugs. Our service platforms include nucleic acid drug discovery, screening and preclinical research services of pharmacology, DMPK and toxicity study for both pharmaceutical companies and academic research institutions. Attributed by its fast and intuitive design of base sequences, the development of nucleic acid drugs is featured with simple materials, convenient preparation processes and affordable production costs, which will greatly shorten the drug development cycle, making it possible to customize individual treatment plans. Hence, it offers a feasible solution for rare diseases and other problems currently plagued.

Cell & Gene Therapy

Cell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. With the rapid development of gene transduction and gene modification technology, delivery vector system, cell culture technology and other fields, gene therapy has made a breakthrough, provide a better solution, concept and idea for intractable diseases (especially rare genetic diseases). Medicilon has established a one-stop research platform for the preclinical R&D of cell & gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.

Relevant newsRelevant news